Web Stats Provided By Google Analytics

Monday, September 16, 2013

ICAAC 2013: Dolutegravir Shows Good Efficacy Across Patient Groups

The new integrase inhibitor dolutegravir worked better than boosted darunavir for people starting HIV treatment for the first time, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Denver.

http://www.hivandhepatitis.com/hiv-treatment/approved-hiv-drugs/4291-icaac-2013-dolutegravir-shows-good-efficacy-across-broad-range-of-patient-groups

No comments:

Post a Comment